TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1853956

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide, 25 mg b.i.d.
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Furosemide, 20 mg b.i.d.
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Furosemide
Number of subjects: 13
Study: 6193123

Group type: EXPERIMENTAL
Intervention: Bleomycin + Cyclophosphamide + Dactinomycin (BCD)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Cisplatinum (CPL)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Fibroblast interferon
Number of subjects: 100

Group type: COMPARATOR
Intervention: Preoperative chemotherapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Surgical resection after preoperative chemotherapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Limb-salvage treatment
Number of subjects: 100

Group type: COMPARATOR
Intervention: Amputation
Number of subjects: 100
Study: 31939556

Group type: EXPERIMENTAL
Intervention: Tai-Geiko exercise (EG)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 19
Study: 30969203

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia
Number of subjects: 194

Group type: COMPARATOR
Intervention: Control (Imagery Exercises)
Number of subjects: 194
Study: 30134964

Group type: EXPERIMENTAL
Intervention: Gonadotropin-releasing hormone (GnRH) antagonist
Number of subjects: 340

Group type: COMPARATOR
Intervention: Progestin-primed ovarian stimulation (PPOS)
Number of subjects: 340
Study: 23870188

Group type: EXPERIMENTAL
Intervention: Foley catheter
Number of subjects: 226

Group type: COMPARATOR
Intervention: Prostaglandin E2 inserts
Number of subjects: 226
Study: 20947591

Group type: EXPERIMENTAL
Intervention: Prilocaine 20 mg and fentanyl 20 µg (Group P)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Bupivacaine 7.5 mg and fentanyl 20 µg (Group B)
Number of subjects: 50
Study: 19723707

Group type: EXPERIMENTAL
Intervention: Three month occupational therapy and physiotherapy programme
Number of subjects: 249

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 249
Study: 17530469

Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg/day)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Fenofibrate (200 mg/day)
Number of subjects: 13
Study: 15207440

Group type: EXPERIMENTAL
Intervention: Pet-therapy intervention group (3/week sessions of almost one-hour visit for 6 weeks with a little cat)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (usual activity programs)
Number of subjects: 28
Study: 16206676

Group type: EXPERIMENTAL
Intervention: Oseltamivir (75 mg twice daily for 5 days)
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Oseltamivir
Number of subjects: 451

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 451
Study: 9144762

Group type: EXPERIMENTAL
Intervention: Watching the video
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: Entering a Quit and Win contest
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: Submitting a quit contract
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: Receiving the booster call
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: Reading the Kick It! guide
Number of subjects: 650

Group type: COMPARATOR
Intervention: Overall intervention use
Number of subjects: 650
Study: 7960167

Group type: EXPERIMENTAL
Intervention: NaF toothpaste (1000 ppm F and 1500 ppm F)
Number of subjects: 4294

Group type: EXPERIMENTAL
Intervention: NaF+TMP toothpaste
Number of subjects: 4294

Group type: COMPARATOR
Intervention: SMFP toothpaste
Number of subjects: 4294
Study: 3676606

Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Phenelzine
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 28502060

Group type: EXPERIMENTAL
Intervention: EZ-blocker
Number of subjects: 70

Group type: COMPARATOR
Intervention: Univent tube (UT)
Number of subjects: 70
Study: 27190088

Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg once daily
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 24550339

Group type: EXPERIMENTAL
Intervention: Single-dose albendazole
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Two doses of albendazole
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Three-day regimen of albendazole
Number of subjects: 175

Group type: COMPARATOR
Intervention: Two-dose regimen compared to single-dose
Number of subjects: 175

Group type: COMPARATOR
Intervention: Three-dose regimen compared to single-dose
Number of subjects: 175
Study: 22203049

Group type: EXPERIMENTAL
Intervention: 15-min neuromuscular warm-up programme carried out twice a week during the 11-week study period
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 52
Study: 20124502

Group type: EXPERIMENTAL
Intervention: Water Exercise Swimming Program (WESP)
Number of subjects: 16
Study: 19032722

Group type: EXPERIMENTAL
Intervention: DrugRCT publications from Europe
Number of subjects: 103211

Group type: COMPARATOR
Intervention: DrugRCT publications from USA
Number of subjects: 103211

Group type: COMPARATOR
Intervention: DrugRCT publications from Australia/Japan
Number of subjects: 103211

Group type: EXPERIMENTAL
Intervention: Citations per publication in Europe
Number of subjects: 103211

Group type: COMPARATOR
Intervention: Citations per publication in USA
Number of subjects: 103211

Group type: COMPARATOR
Intervention: Citations per publication in Australia/Japan
Number of subjects: 103211

Group type: EXPERIMENTAL
Intervention: Proportional increase in publication output from 1995 to 2004 in Europe
Number of subjects: 103211

Group type: COMPARATOR
Intervention: Proportional increase in publication output from 1995 to 2004 in USA
Number of subjects: 103211

Group type: COMPARATOR
Intervention: Proportional increase in publication output from 1995 to 2004 in Australia/Japan
Number of subjects: 103211
Study: 15680715

Group type: EXPERIMENTAL
Intervention: Transcatheter treatment of ASA + PFO
Number of subjects: 141

Group type: COMPARATOR
Intervention: PFO alone
Number of subjects: 141
Study: 12847496

Group type: EXPERIMENTAL
Intervention: Peanut butter skin contact (0.2 mL pressed flat for 1 minute)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Peanut butter inhalation (surface area of 6.3 square inches 12 inches from the face for 10 minutes)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (soy butter mixed with histamine for contact, scent masked with soy butter, tuna, and mint for inhalation)
Number of subjects: 30
Study: 10411769

Group type: EXPERIMENTAL
Intervention: Granisetron 40 microg.kg-1
Number of subjects: 120

Group type: COMPARATOR
Intervention: Droperidol 50 microg.kg-1
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Granisetron 40 microg.kg-1 plus Droperidol 50 microg.kg-1
Number of subjects: 120
Study: 8909671

Group type: EXPERIMENTAL
Intervention: Mivacurium infusion with spontaneous recovery
Number of subjects: 30

Group type: COMPARATOR
Intervention: Neostigmine 0.05 mg/kg and atropine 0.02 mg/kg
Number of subjects: 30
Study: 1498569

Group type: EXPERIMENTAL
Intervention: Norfloxacin ophthalmic solution
Number of subjects: 284

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 284
Study: 6739537

Group type: EXPERIMENTAL
Intervention: 3 mg FK 33‐824
Number of subjects: 16

Group type: COMPARATOR
Intervention: 20 mg diazepam
Number of subjects: 16
Study: 30497955

Group type: EXPERIMENTAL
Intervention: Integrated nursing management model plus routine outpatient care
Number of subjects: 367

Group type: COMPARATOR
Intervention: Routine outpatient care
Number of subjects: 367
Study: 29161695

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided transversus abdominis plane (TAP) block
Number of subjects: 40

Group type: COMPARATOR
Intervention: Local anesthetic infiltration (LAI)
Number of subjects: 40
Study: 27838537

Group type: EXPERIMENTAL
Intervention: HA, CS, curcumin and quercetin per os
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Vaginal estrogens
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: HA, CS, curcumin and quercetin per os with local estrogens
Number of subjects: 145
Study: 24503333

Group type: EXPERIMENTAL
Intervention: Mindfulness intervention focusing on disidentification
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mindfulness intervention focusing on awareness and acceptance
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active control intervention (distraction)
Number of subjects: 0
Study: 23437698

Group type: EXPERIMENTAL
Intervention: Cardiologic rehabilitation (stage 2)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 58
Study: 20714373

Group type: EXPERIMENTAL
Intervention: Tiotropium 5 microg
Number of subjects: 1990

Group type: EXPERIMENTAL
Intervention: Tiotropium 10 microg
Number of subjects: 1990

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1990
Study: 17382476

Group type: EXPERIMENTAL
Intervention: 40 microg/kg rFVIIa administered at first skin incision and a second dose at 90 min later
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 15705619

Group type: EXPERIMENTAL
Intervention: ICSI
Number of subjects: 60

Group type: COMPARATOR
Intervention: IVF
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both ICSI and IVF
Number of subjects: 60
Study: 11923489

Group type: EXPERIMENTAL
Intervention: Undiluted vaccine (10^7.8 pfu/ml)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1:10 dilution (10^6.5 pfu/ml)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1:100 dilution (10^5.0 pfu/ml)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Subjects with vesicles
Number of subjects: 60

Group type: COMPARATOR
Intervention: Subjects without vesicles
Number of subjects: 60
Study: 9892064

Group type: EXPERIMENTAL
Intervention: Fluoxetine, a 5-HT uptake inhibitor, administered orally.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle (control group).
Number of subjects: 0
Study: 7634976

Group type: EXPERIMENTAL
Intervention: Rectally applied sulindac (53 mg/day average)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Rectally applied sulindac (67 mg/day average)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Rectally applied sulindac
Number of subjects: 15
Study: 2229816

Group type: EXPERIMENTAL
Intervention: Butylated hydroxyanisole (BHA)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Butylated hydroxytoluene (BHT)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Diet without BHA and BHT
Number of subjects: 2
Study: 338393

Group type: EXPERIMENTAL
Intervention: Butorphanol 4 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Butorphanol 8 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Pentazocine 50 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 31989379

Group type: EXPERIMENTAL
Intervention: Completion axillary lymph node dissection (ALND)
Number of subjects: 463

Group type: COMPARATOR
Intervention: No completion axillary lymph node dissection (ALND)
Number of subjects: 463
Study: 30284350

Group type: EXPERIMENTAL
Intervention: Transcutaneous tibial nerve stimulation (TTNS)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Sham stimulation (Control)
Number of subjects: 19
Study: 28869987

Group type: EXPERIMENTAL
Intervention: Intensive SBP goal (120 mm Hg)
Number of subjects: 6662

Group type: COMPARATOR
Intervention: Standard SBP goal (140 mm Hg)
Number of subjects: 6662
Study: 25907149

Group type: EXPERIMENTAL
Intervention: Altruistic behavior by P
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 23936562

Group type: EXPERIMENTAL
Intervention: Antivenom treatment
Number of subjects: 120
Study: 21806757

Group type: EXPERIMENTAL
Intervention: Turmeric stain
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Tobacco stain
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Tea stain
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control (no stain)
Number of subjects: 36
Study: 19303414

Group type: EXPERIMENTAL
Intervention: peginterferon alpha‐2a (180 microg once weekly)
Number of subjects: 315

Group type: COMPARATOR
Intervention: lamivudine (100 mg daily)
Number of subjects: 315
Study: 16384840

Group type: EXPERIMENTAL
Intervention: RRR-alpha-tocopherol 400 IU/day + ascorbic acid 500 mg/day (CEalpha)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: RRR-alpha-tocopherol 290 IU/day + RRR-gamma-tocopherol 130 IU/day + ascorbic acid 500 mg/day (CEalphagamma)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control
Number of subjects: 21
Study: 14509498

Group type: COMPARATOR
Intervention: Palliative care consultation to primary care physicians (PCPs); educational and supportive services to patients and their families.
Number of subjects: 90
Study: 10694559

Group type: EXPERIMENTAL
Intervention: Soy tablets
Number of subjects: 177

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 177
Study: 9424324

Group type: EXPERIMENTAL
Intervention: tissue type plasminogen activator (t‐PA) antigen in urine
Number of subjects: 25
Study: 8268142

Group type: EXPERIMENTAL
Intervention: Metronidazole and tripotassium dicitrato bismuthate combined with ranitidine and mylanta (58 patients)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Ranitidine and mylanta (40 patients)
Number of subjects: 127

Group type: COMPARATOR
Intervention: H2-receptor antagonist and antacid (29 patients, H. pylori negative)
Number of subjects: 127
Study: 3512820

Group type: EXPERIMENTAL
Intervention: Intrauterine irrigation with cefazolin solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous cefazolin administration
Number of subjects: 0
Study: 31538829

Group type: EXPERIMENTAL
Intervention: Boneless beef
Number of subjects: 240488

Group type: EXPERIMENTAL
Intervention: Ground beef
Number of subjects: 240488
Study: 29994878

Group type: EXPERIMENTAL
Intervention: Open release of the A1 pulley
Number of subjects: 62

Group type: COMPARATOR
Intervention: Percutaneous release of the A1 pulley
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Both groups (Open and Percutaneous)
Number of subjects: 62
Study: 27221771

Group type: EXPERIMENTAL
Intervention: Orlistat-resveratrol combination (O-R)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Orlistat
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Resveratrol
Number of subjects: 161
Study: 24581876

Group type: EXPERIMENTAL
Intervention: Single-port laparoscopic surgery (SILS)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional laparoscopic appendectomy (LA)
Number of subjects: 120
Study: 22386594

Group type: EXPERIMENTAL
Intervention: Corifollitropin alfa
Number of subjects: 1705

Group type: COMPARATOR
Intervention: Recombinant FSH (rFSH)
Number of subjects: 1705
Study: 20497961

Group type: EXPERIMENTAL
Intervention: Paclitaxel + Bevacizumab (PB)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Paclitaxel + Bevacizumab + Sunitinib (PBS)
Number of subjects: 46
Study: 18555944

Group type: EXPERIMENTAL
Intervention: 0-10 numeric rating scale (NRS) for spasticity severity
Number of subjects: 189
Study: 16130861

Group type: EXPERIMENTAL
Intervention: Tyrian, a self‐etching primer
Number of subjects: 38

Group type: COMPARATOR
Intervention: One‐Step, a single‐bottle adhesive placed after acid etching
Number of subjects: 38
Study: 12382215

Group type: EXPERIMENTAL
Intervention: High-calorie and high-protein blend formula (HP blend) or commercially available supplement (CNS) post-hemodialysis providing 500 kcal and 15 g protein for 1 month.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group received dietary monitoring and counseling but no specific post-HD supplement.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-calorie and high-protein blend formula (HP blend) or commercially available supplement (CNS) post-hemodialysis.
Number of subjects: 0
Study: 10584981

Group type: EXPERIMENTAL
Intervention: Phytohemagglutinin (PHA) stimulation in normal pregnancy group (54 women)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Phytohemagglutinin (PHA) stimulation in RSA group (23 women)
Number of subjects: 77
Study: 7604950

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray
Number of subjects: 0
Study: 2080707

Group type: COMPARATOR
Intervention: C-0 (no compression, n = 36 patients)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: C-10 (compression for 10 min, n = 32 patients)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: C-20 (compression for 20 min, n = 32 patients)
Number of subjects: 100

Group type: COMPARATOR
Intervention: C-0 (no compression)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: C-10 and C-20 (compression for 10 and 20 min)
Number of subjects: 100
Study: 94266

Group type: EXPERIMENTAL
Intervention: creatinol O‐phosphate (COP) 1020 mg administered i.m. twice a day for 3 days
Number of subjects: 10

Group type: COMPARATOR
Intervention: reference substance (solvent of COP) administered i.m. twice a day for 3 days
Number of subjects: 10
Study: 31622732

Group type: EXPERIMENTAL
Intervention: Emibetuzumab + Erlotinib
Number of subjects: 24

Group type: COMPARATOR
Intervention: Erlotinib
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Emibetuzumab + Erlotinib (in patients with high MET expression)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Erlotinib (in patients with high MET expression)
Number of subjects: 24
Study: 31091683

Group type: EXPERIMENTAL
Intervention: StayingFit online program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 28251159

Group type: EXPERIMENTAL
Intervention: Aspirin group
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Balloon group
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Nonballoon group
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 114
Study: 26059214

Group type: EXPERIMENTAL
Intervention: Elastic band exercises for 40 minutes, three times per week for 6 months
Number of subjects: 169

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 169
Study: 23796285

Group type: EXPERIMENTAL
Intervention: 7 days of inpatient hospital treatment (HOSP)
Number of subjects: 139

Group type: COMPARATOR
Intervention: 3 days of inpatient treatment followed by 4 days of home treatment by community nurses (early assisted discharge)
Number of subjects: 139

Group type: COMPARATOR
Intervention: early assisted discharge
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: HOSP
Number of subjects: 139
Study: 21125215

Group type: EXPERIMENTAL
Intervention: 4 h of NBO plus one HBO session (arm A1)
Number of subjects: 385

Group type: COMPARATOR
Intervention: 6 h of normobaric oxygen therapy (NBO; arm A0)
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: 4 h of NBO plus one HBO session (arm B1)
Number of subjects: 385

Group type: COMPARATOR
Intervention: 4 h of NBO plus two HBO sessions (arm B2)
Number of subjects: 385
Study: 19576325

Group type: EXPERIMENTAL
Intervention: Dalcetrapib 300 mg
Number of subjects: 838

Group type: EXPERIMENTAL
Intervention: Dalcetrapib 600 mg
Number of subjects: 838

Group type: EXPERIMENTAL
Intervention: Dalcetrapib 900 mg
Number of subjects: 838

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 838

Group type: EXPERIMENTAL
Intervention: Dalcetrapib (all doses)
Number of subjects: 838

Group type: EXPERIMENTAL
Intervention: Dalcetrapib
Number of subjects: 838

Group type: EXPERIMENTAL
Intervention: Torcetrapib
Number of subjects: 838
Study: 17011712

Group type: EXPERIMENTAL
Intervention: d-amphetamine (0, 8, and 16 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: d-amphetamine
Number of subjects: 20
Study: 15262902

Group type: EXPERIMENTAL
Intervention: Fosinopril (0.1 mg/kg, 0.3 mg/kg, 0.6 mg/kg)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Fosinopril
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78

Group type: COMPARATOR
Intervention: Fosinopril vs Placebo
Number of subjects: 78
Study: 11371412

Group type: EXPERIMENTAL
Intervention: Fexofenadine (180 mg doses over 14 h)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg doses over 36 h)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9267269

Group type: EXPERIMENTAL
Intervention: Full-dose aprotinin
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Half-dose aprotinin
Number of subjects: 133

Group type: COMPARATOR
Intervention: No aprotinin
Number of subjects: 133
Study: 8198266

Group type: EXPERIMENTAL
Intervention: Propofol 10 mg intravenously (i.v.)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Naloxone 2 micrograms/kg
Number of subjects: 40
Study: 3596184

Group type: EXPERIMENTAL
Intervention: YAG laser photocoagulation
Number of subjects: 100

Group type: COMPARATOR
Intervention: BICAP electrocoagulation
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Emergency surgery and mortality
Number of subjects: 100
Study: 31247039

Group type: EXPERIMENTAL
Intervention: Group-based self-management support program (four group-based interactive sessions)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Control group (a single educational lecture)
Number of subjects: 168
Study: 29909435

Group type: EXPERIMENTAL
Intervention: Active PBMt (Photobiomodulation therapy)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo PBMt
Number of subjects: 18
Study: 25967559

Group type: EXPERIMENTAL
Intervention: O-arm navigation
Number of subjects: 32

Group type: COMPARATOR
Intervention: Free-hand technique
Number of subjects: 32
Study: 25050904

Group type: EXPERIMENTAL
Intervention: Resveratrol treatment
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: SIRT1 knock down or inhibition
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 24
Study: 21450565

Group type: EXPERIMENTAL
Intervention: Educational intervention on prescribing behaviour
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 19819469

Group type: EXPERIMENTAL
Intervention: 25 mg/kg of MgSO(4)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: 50 mg/kg of MgSO(4)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 18067438

Group type: EXPERIMENTAL
Intervention: Intervention group (PRECEDE-PROCEED model)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 104